Pharming Group (NASDAQ:PHAR) Shares Down 3.4% – Time to Sell?

Pharming Group (NASDAQ:PHAR) fell 3.4% during mid-day trading on Monday . The stock traded as low as $9.55 and last traded at $9.55. 455 shares traded hands during trading, a decline of 91% from the average session volume of 5,137 shares. The stock had previously closed at $9.89.

Analysts Set New Price Targets

Several brokerages recently issued reports on PHAR. HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Tuesday, December 17th. Jefferies Financial Group started coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, Oppenheimer dropped their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th.

Pharming Group Trading Down 3.1 %

The firm’s 50 day moving average price is $8.60 and its 200-day moving average price is $8.27. The stock has a market cap of $649.86 million, a P/E ratio of -36.85 and a beta of 0.05. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in shares of Pharming Group (NASDAQ:PHAR) by 75.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.